 SYDNEY, June 7, 2021 PRNewswire -- Kazia Therapeutics Limited NASDAQ: KZIA; ASX: KZA, an oncology-focused drug development company, is pleased to announce that a phase II study of Kazias investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study. Key Points Lymphoma is a cancer of white blood cells. 